文献速递消化道肿瘤与早癌

前瞻性II期研究中瑞戈非尼治疗难治性转移性结直肠癌患者的功能影像与循环生物标志物反应

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
PubMed 文献 · Gut · 2017-08-08

本前瞻性II期研究纳入RAS突变转移性结直肠癌患者,采用DCE-MRI和ctDNA动态监测瑞戈非尼疗效。治疗15天后KEF下降>70%与2个月疾病控制率提高、无进展生存期和总生存期改善相关;治疗8周后ctDNA中RAS突变克隆衰减与更好的PFS和OS相关。

要点

  • KEF下降>70%与2个月疾病控制率、PFS和OS改善相关。
  • 治疗8周后ctDNA中RAS突变克隆衰减与更好PFS和OS相关。
  • KEF下降与连续组织活检中CD-31减少相关。

核心结论

  • 联合DCE-MRI和ctDNA可预测瑞戈非尼抗血管生成反应的持续时间,并可能改善患者管理,具有潜在的健康/经济影响。

研究设计与样本

  • 前瞻性II期试验,纳入具有可活检转移灶的RAS突变转移性结直肠癌患者。
  • 治疗前和治疗后第15天采集DCE-MRI,每月收集ctDNA直至疾病进展,并用微滴数字PCR检测克隆性RAS突变。
  • 对70份连续组织活检进行免疫组化CD-31评分。

主要发现

  • 27例患者有配对DCE-MRI扫描;KEF中位下降58.2%。
  • 23例有结局数据的患者中,KEF下降>70%(6/23)与2个月时RECIST V.1.1评估的更高疾病控制率相关(p=0.048)。
  • KEF下降>70%与改善的PFS相关(HR 0.16,95%CI 0.04-0.72,p=0.02),4个月PFS为66.7% vs 23.5%,OS相关(HR 0.08,95%CI 0.01-0.63,p=0.02)。
  • KEF下降与连续组织活检中CD-31减少相关(p=0.04)。
  • 治疗8周后ctDNA中RAS突变克隆衰减与更好PFS相关(HR 0.21,95%CI 0.06-0.71,p=0.01),与OS相关(HR 0.28,95%CI 0.07-1.04,p=0.06)。

临床怎么用

  • 作者认为联合DCE-MRI和ctDNA可预测瑞戈非尼抗血管生成反应的持续时间,并可能改善患者管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better patient selection. DESIGN: Patients with RAS mutant mCRC with biopsiable metastases were enrolled in this phase II trial. Dynamic contrast-enhanced (DCE) MRI was acquired pretreatment and at day 15 post-treatment. Median values of volume transfer constant (Ktrans), enhancing fraction (EF) and their product KEF (summarised median values of Ktrans× EF) were generated. Circulating tumour (ct) DNA was collected monthly until progressive disease and tested for clonal RAS mutations by digital-droplet PCR. Tumour vasculature (CD-31) was scored by immunohistochemistry on 70 sequential tissue biopsies. RESULTS: Twenty-seven patients with paired DCE-MRI scans were analysed. Median KEF decrease was 58.2%. Of the 23 patients with outcome data, >70% drop in KEF (6/23) was associated with higher disease control rate (p=0.048) measured by RECIST V. 1.1 at 2 months, improved progression-free survival (PFS) (HR 0.16 (95% CI 0.04 to 0.72), p=0.02), 4-month PFS (66.7% vs 23.5%) and overall survival (OS) (HR 0.08 (95% CI 0.01 to 0.63), p=0.02). KEF drop correlated with CD-31 reduction in sequential tissue biopsies (p=0.04). RAS mutant clones decay in ctDNA after 8 weeks of treatment was associated with better PFS (HR 0.21 (95% CI 0.06 to 0.71), p=0.01) and OS (HR 0.28 (95% CI 0.07-1.04), p=0.06). CONCLUSIONS: Combining DCE-MRI and ctDNA predicts duration of anti-angiogenic response to regorafenib and may improve patient management with potential health/economic implications.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Khan K, Rata M, Cunningham D, et al. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut. 2017. PMID: 28790159. doi:10.1136/gutjnl-2017-314178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。